Drug Trial Radar · NCT05281471
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Aug 31, 2022
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Genelux CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- GOG Foundation
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High-grade Serous Ovarian Cancer
- Endometrioid Ovarian Cancer
- Ovarian Clear Cell Carcinoma
Interventions
olvimulogene nanivacirepvecBiological
Olvi-Vec is an engineered oncolytic vaccinia virus
Platinum chemotherapy: carboplatin (preferred) or cisplatinDrug
Administered according to local practice
Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicinDrug
Administered according to local practice
Bevacizumab (or biosimilar)Drug
Administered according to local practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment)Time frame: From date of randomization up to 12 months
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
The University of South Alabama, Mitchell Cancer Institute
Mobile, Alabama · Recruiting
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
UC San Diego Health - Moores Cancer Center
La Jolla, California · Recruiting
Hoag Gynecologic Oncology
Newport Beach, California · Recruiting
UCI Health Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
AdventHealth Cancer Institute
Orlando, Florida · Recruiting
Sarasota Memorial Healthcare System
Sarasota, Florida · Recruiting
Women's Cancer Associates with Women's Care Florida
St. Petersburg, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
Holy Cross Hospital
Silver Spring, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Mercy Hospital St. Louis
St Louis, Missouri · Recruiting
Women's Cancer Center of Nevada
Las Vegas, Nevada · Recruiting
Center of Hope
Reno, Nevada · Recruiting
Stony Brook Cancer Center
Stony Brook, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Atrium Health Wake Forest Baptist, Comprehensive Cancer Center
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
OhioHealth Research Institute
Columbus, Ohio · Recruiting
Kettering Health
Kettering, Ohio · Recruiting
ProMedica Flower Hospital
Sylvania, Ohio · Recruiting
Oklahoma University Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
AHN West Penn Hospital
Pittsburgh, Pennsylvania · Recruiting
Hollings Cancer Center
Charleston, South Carolina · Recruiting
Erlanger Health, Inc.
Chattanooga, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
University of Texas Science Center at Houston, McGovern Medical School
Houston, Texas · Recruiting
Providence Sacred Heart Medical Center & Children's Hospital
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.